Effect of disposition of Mannich antimalarial agents on their pharmacology and toxicology

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 9, 1998, Pages 2410-2416

  Ruscoe, J E ^a,c   Tingle, M D ^a,b   O'Neill, P M ^a   Ward, S A ^a   Park, B K ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; AMOPYROQUINE; ANTIMALARIAL AGENT; CYCLOQUINE; MANNICH BASE; PYRONARIDINE; PYROQUINE; QUINOLINE DERIVATIVE; TEBUQUINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; DRUG ACCUMULATION; DRUG ACTIVATION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIPOPHILICITY; MALARIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0031660992     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.9.2410     Document Type: Article

References (33)

1. 4-substituted 2,7-(and 2,8-)bis(triefluoromethyl)quinolin-4-amines. Austr. J. Chem. 38:1827-1835.
2. Basco, L. K., and J. Le Bras. 1992. In vitro activity of pyronaridine against African strains of Plasmodium falciparum. Ann. Trop. Med. Parasitol. 86: 447-454.
3. Betschart, H. R., W. R. Jondorf, and M. H. Bickel. 1988. Differences in adipose tissue distribution of basic lipophilic drugs between intraperitoneal and other routes of administration. Xenobiotica 18:113-121.
4. Bray, G., and S. A. Ward. 1993. Malaria chemotherapy: resistance to quinoline containing drugs in Plasmodium falciparum. FEMS Microbiol. Lett. 113:1-8.
5. Burckhalter, J. H., J. H. Tendwick, F. H. Jones, P. A. Jones, W. F. Holcome, and A. L. Rawlins. 1948. Aminoalkylphenols as antimalarials. II. (Heterocyclic-amino)-α-amino-o-cresols: the synthesis of camoquine. J. Am. Chem. Soc. 70:1363-1373.
6. Harrison, A. C., N. R. Kitteringham, J. B. Clarke, and B. K. Park. 1992. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 43:1412-1430.
7. Hatton, C. S. R., T. E. A. Peto, C. Bunch, and G. Pasvol. 1986. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet i:411-413.
8. Hawley, S. R., P. G. Bray, and S. A. Ward. 1996. Amodiaquine accumulation in Plasmodium falciparum as a possible explanation for its superior antimalarial activity over chloroquine. Mol. Biochem. Parasitol. 80:15-25.
9. Jaeger, A., P. Sauder, J. Kopferschmitt, and F. Flesch. 1987. Clinical features and management of poisoning due to antimalarial drugs. Med. Toxicol. 2:242-273.
10. Jewell, H., J. L. Maggs, A. C. Harrison, P. M. O'Neill, J. E. Ruscoe, and B. K. Park. 1995. The role of hepatic metabolism in the bioactivation and detoxication of amodiaquine. Xenobiotica 25:199-217.
11. Larrey, D., A. Castot, D. Pessayre, P. Merigot, J. P. Machayekhy, G. Feldamn, A. Lenoir, B. Ruelt, and J. P. Benhamov. 1986. Amodiaquine-induced hepatitis. Ann. Int. Med. 104:801-803.
12. Laurent, F., S. Saivin, P. Chretien, J. F. Magnaval, F. Peyron, A. Sqalli, A. E. Tufenkji Y. Coulais, H. Baba, G. Campistron, H. Regis, P. Ambroise-Thomas, A. Bryskier, and G. Houin. 1993. Pharmacokinetic and pharmacodynamic study of amodiaquine and its two metabolites after single oral dose in human volunteers. Arzneim.-Forsch./Drug Res. 43:612-616.
13. Moor, M. J., S. H. Steiner, G. Jachertz, and M. H. Bickel. 1992. Adipose tissue distribution and chemical structure of basic lipophilic drugs: desipramine, N-acetyl desipramine, and haloperidol. Pharmacol. Toxicol. 70:121-124.
14. Naisbitt, D. J., J. E. Ruscoe, D. Williams, P. M. O'Neill, M. Pirmohamed, and B. K. Park 1997. Disposition of amodiaquine and related antimalarials in human neutrophils. Implications for drug design. J. Pharmacol. Exp. Ther. 280:884-893.
15. Neftel, K. A., W. Woodtly, M. Schmid, P. G. Frink, and J. Fehr. 1986. Amodiaquine induced agranulocytosis and liver damage. Br. Med. J. 292: 721-723.
16. O'Neill, P. M., D. J. Willcock, S. R. Hawley, P. G. Bray, R. C. Storr, S. A. Ward, and B. K. Park. 1997. 4-Aminoquinolines - past, present and future: a chemical perspective. Submitted for publication.
17. O'Neill, P. M., et al. Unpublished data.
18. Peters, W., and B. L. Robinson. 1992. The chemotherapy of rodent malaria. XLVII. Studies on pyronaridine and other Mannich base antimalarials. Ann. Trop. Med. Parasitol. 86:455-465.
19. Rouveix, B., L. Coulombel, J. P. Aymard. F. Chau, and L. Abel. 1989. Amodiaquine-induced immune agranulocytosis. Br. J. Haematol. 71:7-11.
20. Ruscoe, J. E., H. Jewell, J. L. Maggs, P. M. O'Neill, C. R. Storr, S. A. Ward, and B. K. Park. 1995. The effect of chemical substitution on the metabolic activation, metabolic detoxication, and pharmacological activity of amodiaquine in the mouse. J. Pharmacol. Exp. Ther. 273:393-404.
21. Shao, B. R. 1990. A review of antimalarial drug pyronaridine. Chin. Med. J. 103:428-434.
22. Thomson, P. E., and L. M. Werbel. 1972. Antimalarial agents: chemistry and pharmacology. Academic Press, Inc., New York, N.Y.
23. Tingle, M. D., H. Jewell, J. L. Maggs, P. M. O'Neill, and B. K. Park. 1995. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution. Biochem. Pharmacol. 50:1113-1119.
24. Tuffery, A. A. 1987. Laboratory animals: an introduction for new experimenters. Wiley, Chichester, United Kingdom.
25. Watkins, W., D. Sixsmith, H. Spencer, D. Boriga, D. Kariuka, and T. Kipingor. 1984. Effectiveness of amodiaquine as treatment for chloroquine-resistant Plasmodium falciparum infections in Kenya. Lancet i:357-359.
26. Watkins, W. M., and M. Mosobo. 1993. Treatment of Plasmodium falaciparum malaria with pyrimethamine and sulphadoxine: a selective pressure for resistance is a function of long elimination half-life. Trans. R. Soc. Trop. Med. Hyg. 87:75-79.
27. Werbel, L. M., and H. Chung (Walter Reed Army Institute of Research). Personal communication.
28. Werbel, L. M., P. D. Cook, E. F. Elslager, J. H. Hung, J. L. Johnson, S. J. Keston, D. J. McNamara, D. F. Ortwine, and D. F. Wroth. 1986. Synthesis, antimalarial activity and quantitative structure-activity relationships of tebuquine and a series of related 5-[(7-chloro-4quinolinyl)amino]-3-[(alkylamino)methyl][1,1′-biphenyl]-2- ols and N-oxides. J. Med. Chem. 29:924-939.
29. Winstanley, P. A. 1996. Pyronaridine: a promising drug for Africa. Lancet 347:2-3.
30. Winstanley, P. A., I. G. Edwards, M. L. Orme, and A. M. Breckenridge. 1987. The disposition of amodiaquine in man after oral administration. Br. J. Clin. Pharmacol. 23:1-7.
31. Yamamoto, A., S. Adachi, Y. Matsuzawa, T. Kitani, A. Hiraoka, and K. Seki. 1976. Studies on drug induced lipidosis. VII. Effects of bis-(-diethyl-aminoethylther of hexestrol, chloroquine, homochlorocyclizine prenylamine and diazacholestrol on the lipid composition of rat liver and kidney. Lipid 11: 616-622.
32. Yayon, A., Z. I. Cabantchik, and H. Ginsburg. 1984. Identification of the acidic compartment of Plasmodium falciparum-infected human erythrocytes as the target of the antimalarial drug chloroquine. EMBO J. 11:2695-2700.
33. Zamora, J. M., H. L. Pearce, and W. T. Beck. 1988. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukaemic cells. Mol. Pharmacol. 33:454-162.